1209 related articles for article (PubMed ID: 7844597)
21. [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
Sun XF; Zhen ZJ; Xiang XJ; Ling JY; Peng RJ; Xia Y; Zheng L; Luo WB; Lin H; Guan ZZ
Ai Zheng; 2009 May; 28(5):506-10. PubMed ID: 19624879
[TBL] [Abstract][Full Text] [Related]
22. Therapy of B-cell acute lymphoblastic leukaemia in childhood: the BFM experience.
Reiter A
Baillieres Clin Haematol; 1994 Jun; 7(2):321-37. PubMed ID: 7803904
[TBL] [Abstract][Full Text] [Related]
23. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
24. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
[TBL] [Abstract][Full Text] [Related]
25. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: Classification and allocation to strategic therapy groups. BIF study group].
Reiter A; Tiemann M; Ludwig WD; Wacker HH; Yakisan E; Schrappe M; Henzler D; Sykora KW; Brandt A; Odenwald E
Klin Padiatr; 1994; 206(4):222-33. PubMed ID: 7967418
[TBL] [Abstract][Full Text] [Related]
26. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
27. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
[TBL] [Abstract][Full Text] [Related]
29. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
30. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
[TBL] [Abstract][Full Text] [Related]
31. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
[TBL] [Abstract][Full Text] [Related]
32. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
[TBL] [Abstract][Full Text] [Related]
33. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
Karakas T; Bergmann L; Stutte HJ; Jäger E; Knuth A; Weidmann E; Mitrou PS; Hoelzer D
Leuk Lymphoma; 1996 Dec; 24(1-2):121-9. PubMed ID: 9049968
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
35. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
36. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol.
Atra A; Gerrard M; Hobson R; Imeson JD; Ashley S; Pinkerton CR
Br J Cancer; 1998 Jun; 77(12):2281-5. PubMed ID: 9649146
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma.
Mann G; Attarbaschi A; Burkhardt B; Niggli F; Klapper W; Ludwig WD; Schrappe M; Zimmermann M; Gadner H; Reiter A;
Br J Haematol; 2007 Nov; 139(3):443-9. PubMed ID: 17868047
[TBL] [Abstract][Full Text] [Related]
38. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Moleti ML; Testi AM; Giona F; Malandruccolo L; Pescarmona E; Martino P; Paoloni F; Barberi W; Palumbo G; Mandelli F; Foa R
Leuk Lymphoma; 2007 Mar; 48(3):551-9. PubMed ID: 17454598
[TBL] [Abstract][Full Text] [Related]
39. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
40. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
